9-[(S)-3-羟基-2-(膦酰甲氧基)丙基]腺嘌呤 | 92999-29-6

• 物质功能分类: 有机原料 - 有机膦化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 9-[(S)-3-羟基-2-(膦酰甲氧基)丙基]腺嘌呤
• 英文名称: (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine
• 英文别名: Hpmpa；[(2S)-1-(6-aminopurin-9-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
• CAS: 92999-29-6
• 化学式: C₉H₁₄N₅O₅P
• 分子量: 303.214
• InChiKey: FRPXSOOHWNMLPH-LURJTMIESA-N

物化性质

• 熔点：
  255-257 °C
• 沸点：
  719.6±70.0 °C(Predicted)
• 密度：
  1.91±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  157
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  9-[(S)-3-羟基-2-(膦酰甲氧基)丙基]腺嘌呤 在 morpholino-N,N'-dicyclohexylguanidine 、 N,N'-二环己基碳二亚胺 作用下， 以 水 、 叔丁醇 为溶剂， 反应 6.0h， 以89%的产率得到环-9-(3-羟基-2-膦酰基甲氧基丙基)腺嘌呤
  参考文献：
  名称：

  Rosenberg, Ivan; Holy, Antonin, Collection of Czechoslovak Chemical Communications, 1987, vol. 52, # 11, p. 2792 - 2800

  摘要：

  DOI：
• 作为产物：
  描述：

  9-[(2S)-2,3-二羟基丙基]-9H-嘌呤-6-胺 在 吡啶 、 sodium hydride 、 N,N-二甲基甲酰胺 、 N,N'-二环己基碳二亚胺 作用下， 反应 25.0h， 生成 9-[(S)-3-羟基-2-(膦酰甲氧基)丙基]腺嘌呤
  参考文献：
  名称：

  合成光学活性烷基化腺嘌呤衍生物的新方法。

  摘要：

  提出了一种新的手性无环核苷和核苷酸类似物的合成方法，从d（-）-或l（+）-核糖开始。评估了合成化合物对痘病毒家族的抗病毒特性。

  DOI：

  10.1016/j.bmcl.2003.12.107

文献信息

• [EN] NOVEL BROAD SPECTRUM ANTIVIRAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTIVIRAUX À LARGE SPECTRE
  申请人：UNIV SOUTHERN CALIFORNIA

  公开号：WO2018081785A1

  公开（公告）日：2018-05-03

  An antiviral compound of the following formula (I) is provided or a salt or a pharmaceutically acceptable salt thereof, where B is a naturally occurring or non-naturally occurring base; R1 is a C2-C14 alkyl group; X is O, S, CH=CH (cis) or CH=CH (trans); and R2 is a C2-C14 alkyl group. In some embodiments, B can be adenine or cytosine. Compositions containing the compound, and methods of using and preparing the compound, are also provided.

  提供了以下式（I）的抗病毒化合物或其盐或药用可接受的盐，其中B是自然存在或非自然存在的碱基；R1是C2-C14烷基基团；X是O、S、CH=CH（顺式）或CH=CH（反式）；R2是C2-C14烷基基团。在某些实施例中，B可以是腺嘌呤或胞嘧啶。还提供了含有该化合物的组合物以及使用和制备该化合物的方法。
• [EN] NUCLEOTIDE ANALOGS<br/>[FR] ANALOGUES NUCLÉOTIDIQUES
  申请人：UNIV CALIFORNIA

  公开号：WO2016044281A1

  公开（公告）日：2016-03-24

  Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection. In one embodiment, the invention describes compounds with antiviral activity against a papillomavirus in the absence of a significant antiproliferative host cell effect. Therefore, the invention includes antiviral agents that selectively inhibit and/or block viral DNA synthesis and/or the production of virions of high risk HPV types.

  本文披露了无环核苷酸类似物及其用于治疗和/或改善乳头状瘤病毒感染的方法。在一种实施方式中，本发明描述了具有抗病毒活性的化合物，用于对抗乳头状瘤病毒，而不对宿主细胞的增殖产生显著影响。因此，该发明包括选择性抑制和/或阻断高危型HPV病毒DNA合成和/或病毒颗粒产生的抗病毒药物。
• Method to improve antiviral activity of nucleotide analogue drugs
  申请人：McKenna Charles E.

  公开号：US09550803B2

  公开（公告）日：2017-01-24

  An amino acid conjugate of a cyclic or acyclic nucleoside phosphonate is provided. In some cases, the amino acid conjugate is a tyrosine alkyl amide phosphonate ester conjugate of a cyclic or acyclic nucleoside phosphonate, and is useful as an antiviral compound. In certain cases, the tyrosine conjugate includes a long chain alkyl group on the carboxamide group of the tyrosine residue. In a method of preparing an acyclic tyrosine conjugate, a tert-butyloxycarbonyl (Boc) protected tyrosine residue containing a long chain alkyl group is reacted with an acyclic nucleoside phosphonate mono-ethyl ester in the presence of benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate to produce a Boc-protected nucleoside phosphonate di-ester, and the di-ester is deethylated and deprotected to produce the tyrosine conjugate. Methods of inhibiting viral replication and methods of treating a viral infection using the amino acid conjugate are also provided.

  提供了一个环状或非环状核苷酸膦酸的氨基酸共轭物。在某些情况下，氨基酸共轭物是环状或非环状核苷酸膦酸的酪氨酸烷基酰胺膦酸酯共轭物，并且可用作抗病毒化合物。在某些情况下，酪氨酸共轭物包括酪氨酸残基的羧酰胺基上的长链烷基基团。在制备非环状酪氨酸共轭物的方法中，将含有长链烷基基团的叔丁氧羰基（Boc）保护的酪氨酸残基与非环状核苷酸膦酸单乙酯酯在苯并三唑-1-氧基三吡咯磷六氟磷酸存在下反应，产生一个Boc保护的核苷酸膦酸二酯，然后去乙酯化和去保护以产生酪氨酸共轭物。还提供了使用氨基酸共轭物抑制病毒复制和治疗病毒感染的方法。
• General Method of Preparation of N-[(S)-(3-Hydroxy-2-phosphonomethoxypropyl)] Derivatives of Heterocyclic Bases
  作者：Petr Alexander、Antonín Holý

  DOI：10.1135/cccc19931151

  日期：——

  Reaction of (R)-1-O-p-toluenesulfonyl-1,2,3-propanetriol (IV) with N-trimethylacetylimidazole (II) afforded (R)-1-O-p-toluenesulfonyl-3-O-trimethyacetyl-1,2,3-propanetriol (V) which was reacted with dimethoxymethane in the presence of phosphorus pentoxide to give (R)-2-O-methoxymethyl-1-O-p-toluenesulfonyl-3-O-trimethyacetyl-1,2,3-propanetriol (VI). Compound VI was treated with acetic anhydride and boron trifluoride etherate and the obtained 2-acetoxy derivative VII reacted with bromotrimethylsilane to give the intermediary bromomethyl ether VIII. Compound VIII on reaction with tris(2-propyl) phosphite afforded (R)-2-O-bis(2-propyl)phosphonomethyl-1-O-p-toluenesulfonyl-3-O-trimethyacetyl-1,2,3-propanetriol (IX). Condensation of synthon IX with sodium salts of adenine, 2,6-diaminopurine, or with cytosine, 6-azacytosine or 2-chloroadenine in the presence of cesium carbonate, afforded fully protected diesters X and XIIIb which on methanolysis and reaction with bromotrimethylsilane gave N-[(S)-(3-hydroxy-2-phosphonomethoxypropyl)] derivatives of adenine (XIa), 2- chloroadenine (XIb), 2,6-diaminopurine (XIc), cytosine (XIVa) and 6-azacytosine (XIVb). In an analogous reaction, sodium salt of 4-methoxy-2-pyrimidone reacted with compound IX to give an intermediate XIIIa which on treatment with methanolic ammonia and subsequent deblocking under the same conditions also afforded the cytosine derivative XIVa. Sodium salt of 2-amino-6-chloropurine was in this way converted into the corresponding 2-aminopurine derivative XVIII. Deprotection of this compound gave 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)-2-aminopurine (XIX).

  将(R)-1-O-p-甲苯磺酰基-1,2,3-丙三醇 (IV) 与N-三甲基乙酰亚咪唑 (II) 反应得到 (R)-1-O-p-甲苯磺酰基-3-O-三甲基乙酰基-1,2,3-丙三醇 (V)，将其与磷五氧化物存在下与二甲氧基甲烷反应，得到 (R)-2-O-甲氧基甲基-1-O-p-甲苯磺酰基-3-O-三甲基乙酰基-1,2,3-丙三醇 (VI)。化合物 VI 经过乙酸酐和三氟硼醚的处理，得到2-乙酰氧基衍生物 VII，再与溴三甲基硅烷反应得到中间体溴甲醚 VIII。化合物 VIII 与三(2-丙基)磷酸酯反应得到 (R)-2-O-双(2-丙基)磷酰甲基-1-O-p-甲苯磺酰基-3-O-三甲基乙酰基-1,2,3-丙三醇 (IX)。将合成物 IX 与腺嘌呤、2,6-二氨基嘌呤的钠盐或胞嘧啶、6-氮杂胞嘧啶或2-氯腺嘌呤在碳酸铯存在下缩合，得到完全保护的二酯物 X 和 XIIIb，经过甲醇解和与溴三甲基硅烷反应，得到腺嘌呤 (XIa)、2-氯腺嘌呤 (XIb)、2,6-二氨基嘌呤 (XIc)、胞嘧啶 (XIVa) 和 6-氮杂胞嘧啶 (XIVb) 的N-[(S)-(3-羟基-2-磷酸甲氧基丙基)]衍生物。类似地，4-甲氧基-2-吡啶酮的钠盐与化合物 IX 反应得到中间体 XIIIa，经过甲醇氨解和相同条件下的脱保护反应，也得到胞嘧啶衍生物 XIVa。2-氨基-6-氯嘌呤的钠盐以这种方式转化为相应的2-氨基嘌呤衍生物 XVIII。对这种化合物的去保护得到9-[(S)-(3-羟基-2-磷酸甲氧基丙基)]-2-氨基嘌呤 (XIX)。
• Syntheses of Enantiomeric N-(3-Hydroxy-2-phosphonomethoxypropyl) Derivatives of Purine and Pyrimidine Bases
  作者：Antonín Holý

  DOI：10.1135/cccc19930649

  日期：——

  Methods of preparation of N-(3-hydroxy-2-phosphonomethoxypropyl) (HPMP) derivatives of (2S)- and (2R)-configuration (compounds I and XXVII, respectively) are described. The general method starts from the corresponding N-(2,3-dihydroxypropyl) derivatives which were converted either into the (R)-enantiomers XIII by reaction of the base with (R)-glycidol butyrate (XII) in the presence of cesium carbonate and subsequent methanolysis, or into the (S)-enantiomers XI by alkylation of the base with (R)-2,2-dimethyl-4-tosyloxymethyl-1,3-dioxolane (V) in the presence of the same reagent. The amino groups on the heterocyclic base in compounds XI and XIII were benzoylated by silylation followed by reaction with benzoyl chloride and the obtained N-benzoates XV and XVII on reaction with trityl chloride afforded the corresponding 3'-O-trityl derivatives XVI and XVIII. These compounds were condensed with bis(2-propyl) p-sulfonyloxymethylphosphonate (XXIII) in dimethylformamide in the presence of sodium hydride to give the fully protected diesters XXIV and XXVIII. These compounds could be selectively acid-hydrolyzed to remove the trityl group only under formation of compounds XXXV, or methanolyzed and then acid-hydrolyzed to remove the trityl and N-benzoyl groups and lead to compounds XXVI and XXX, or treated with bromotrimethylsilane to remove the trityl and 2-propyl group to give phosphonates of the type XXXI. All the three types of compounds were then converted into free phosphonates of the (S)-series (I) and the (R)-series (XXVII). Derivatives of cytosine (Ia, XXVIIa), adenine (Ib, XXVIIb), 2,6-diaminopurine (Ic, XXVIIc) and guanine (Id, XXVIId) were prepared. Condensation of the partially blocked adenine deriavtive XXXV with the tosyl derivative XXIII and subsequent deprotection afforded 9-(S)-(2,3-diphosphonomethoxy propyl)adenine (XLIII). Reaction of the same compound XXXV or its (R)-enantiomer XXXVIII with diethyl phosphonate , followed by deblocking, afforded 3'-O-phosphoryl derivatives (S)-HPMPA (XXXVII) and (R)-HPMPA (XL).

  描述了制备N-(3-羟基-2-膦甲氧基丙基)（HPMP）衍生物的方法，其中包括（2S）-和（2R）-构型的化合物I和XXVII。一般方法始于相应的N-(2,3-二羟基丙基)衍生物，通过将其转化为（R）-对映体XIII（通过碱与（R）-环氧丙酯（XII）在碳酸铯存在下的反应和随后的甲醇解）或通过在相同试剂存在下，通过碱与（R）-2,2-二甲基-4-对甲苯磺酰氧甲基-1,3-二氧兰（V）烷基化，将其转化为（S）-对映体XI。化合物XI和XIII中的杂环碱基上的氨基被硅烷化后与苯甲酰氯反应，得到的N-苯甲酸酯XV和XVII在与三苯甲基氯反应时生成相应的3'-O-三苯甲基衍生物XVI和XVIII。这些化合物与双(2-丙基)对磺酸氧甲基膦酸酯（XXIII）在二甲基甲酰胺中与氢化钠存在下反应，得到完全保护的二酯体XXIV和XXVIII。这些化合物可以选择性地酸水解以去除三苯甲基基团，仅形成化合物XXXV，或者经甲醇解然后酸水解以去除三苯甲基和N-苯甲酰基团，并导致化合物XXVI和XXX，或者经溴三甲基硅烷处理以去除三苯甲基和2-丙基基团，形成XXXI型膦酸酯。然后将这三种类型的化合物转化为（S）-系列（I）和（R）-系列（XXVII）的自由膦酸酯。制备了胞嘧啶（Ia、XXVIIa）、腺嘌呤（Ib、XXVIIb）、2,6-二氨基嘌呤（Ic、XXVIIc）和鸟嘌呤（Id、XXVIId）的衍生物。部分阻塞的腺嘌呤衍生物XXXV与甲磺酰衍生物XXIII进行缩合反应，随后去保护作用，得到9-(S)-(2,3-二磷酸甲氧基丙基)腺嘌呤（XLIII）。将相同化合物XXXV或其（R）-对映体XXXVIII与二乙基膦酸酯反应，随后去保护，得到3'-O-磷酰化衍生物（S）-HPMPA（XXXVII）和（R）-HPMPA（XL）。